Hearn Jasmine H, Martin Sarah, Smith Melanie
The Department of Psychology, Manchester Metropolitan University, UK.
Manchester & Salford Pain Centre, Irving Building, Salford Royal NHS Foundation Trust, UK.
Br J Pain. 2023 Feb;17(1):71-86. doi: 10.1177/20494637221132451. Epub 2022 Oct 11.
Chronic pain is a leading cause of disability, often requiring multidisciplinary management. 2021 NICE guidance has questioned the quality of the evidence surrounding the efficacy of pain management programmes (PMPs), with only minor benefit demonstrated in psychological and physical outcomes. There is need for further high-quality evidence for the efficacy of PMPs for a range of chronic pain conditions and to identify barriers to successful management of chronic pain.
This service evaluation utilised routinely collected outcome data of 508 PMP attendees to investigate change in pain- and patient-related outcomes across two distinct PMPs; a standard and an intensive PMP, and establish their longer-term efficacy and appropriateness for patients with differing degrees of need.
More people with chronic widespread pain, fibromyalgia, and osteoarthritis were referred to the intensive PMP (reflecting greater disability and distress in these conditions). Those referred to the intensive PMP demonstrated greater distress (such as more severe depression and anxiety), lower pain acceptance and poorer physical function. Improvements were observed in all outcomes across both PMPs (including physical function, pain catastrophising and pain acceptance). Depression and disability demonstrated clinically meaningful improvements in the intensive PMP, and pain severity showed clinically meaningful improvement in both PMPs. However, depression severity, disability, pain severity, and pain interference significantly deteriorated at 6-month follow-up for those on the intensive PMP, with pain severity increasing to a clinically meaningful degree (by more than 10%), though these outcomes remained better than at baseline.
This evaluation identified that people with chronic pain most at risk of deterioration in physical and psychological wellbeing after completing a PMP require early identification to mitigate such deterioration. Established and emerging PMPs need to be tailored to the needs of this group, particularly at follow-up to reduce risks of pain severity increasing, alongside establishing/reinforcing safeguards against deterioration post-PMP.
慢性疼痛是导致残疾的主要原因,通常需要多学科管理。2021年英国国家卫生与临床优化研究所(NICE)的指南对疼痛管理项目(PMPs)疗效的证据质量提出了质疑,在心理和身体方面的结果仅显示出轻微益处。对于一系列慢性疼痛病症的PMPs疗效,需要进一步的高质量证据,以确定慢性疼痛成功管理的障碍。
本服务评估利用508名PMP参与者的常规收集结果数据,调查两种不同PMPs(标准PMP和强化PMP)中疼痛和患者相关结果的变化,并确定它们对不同需求程度患者的长期疗效和适用性。
更多患有慢性广泛性疼痛、纤维肌痛和骨关节炎的患者被转诊至强化PMP(这反映出这些病症中更大的残疾和痛苦程度)。被转诊至强化PMP的患者表现出更大的痛苦(如更严重的抑郁和焦虑)、更低的疼痛接受度和更差的身体功能。在两种PMPs中,所有结果均有改善(包括身体功能、疼痛灾难化和疼痛接受度)。在强化PMP中,抑郁和残疾状况有临床意义的改善,在两种PMPs中疼痛严重程度均有临床意义的改善。然而,对于强化PMP组的患者,在6个月随访时,抑郁严重程度、残疾、疼痛严重程度和疼痛干扰显著恶化,疼痛严重程度增加到有临床意义的程度(超过10%),尽管这些结果仍优于基线水平。
本评估发现,完成PMP后身体和心理健康最有可能恶化的慢性疼痛患者需要尽早识别,以减轻这种恶化。既定的和新出现的PMPs需要根据这一群体的需求进行调整,特别是在随访时,以降低疼痛严重程度增加的风险,同时建立/加强防止PMP后病情恶化的保障措施。